Amyloidosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

1
Amyloidosis Therapeutics - Pipeline Assessment
and Market Forecasts to 2019 Amyloidosis
Therapeutics - Pipeline Assessment and Market
Forecasts to 2019. The report is an essential
source of information and analysis on the global
Amyloidosis Therapeutics market. The report
identifies the key trends shaping and driving the
global Amyloidosis Therapeutics market. To
Browse This Report Kindly Visit
http//www.aarkstore.com/reports/Amyloidosis-Thera
peutics-Pipeline-Assessment-and-Market-Forecasts-t
o-2019-198822.html
2
Amyloidosis Therapeutics - Pipeline Assessment
and Market Forecasts to 2019SummaryCompany,
the industry analysis specialist, has released
its new report, Amyloidosis Therapeutics -
Pipeline Assessment and Market Forecasts to
2019. The report is an essential source of
information and analysis on the global
Amyloidosis Therapeutics market. The report
identifies the key trends shaping and driving the
global Amyloidosis Therapeutics market. The
report also provides insights on the prevalent
competitive landscape and the emerging players
expected to significantly alter the market
positioning of the current market leaders. Most
importantly, the report provides valuable
insights on the pipeline products within the
global Amyloidosis Therapeutics sector. This
report is built using data and information
sourced from proprietary databases, primary and
secondary research and in-house analysis by
Company team of industry experts.ScopeThe
report provides information on the key drivers
and challenges of the Amyloidosis Therapeutics
market. Its scope includes - - Annualized seven
key markets (US, France, Germany, Italy, Spain,
UK and Japan) Amyloidosis Therapeutics market
revenues data from 2006 to 2011, forecast for
eight years to 2019. - Pipeline analysis data
providing a split across the different phases,
mechanisms of action being developed and emerging
trends by seven key markets. Pipeline candidates
fall under major therapeutic classes.- Analysis
of the current and future competition in the
seven key countries Amyloidosis Therapeutics
market. - Insightful review of the key industry
drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative
analysis of its implications. - Key topics
covered include strategic competitor assessment,
market characterization, unmet needs and the
implications for the Amyloidosis Therapeutics
market.- Analysis of key recent licensing and
partnership agreements in Amyloidosis
Therapeutics market
3
Reasons to buyThe report will enhance
your decision making capability. It will allow
you to - - Develop and design your in-licensing
and out-licensing strategies through a review of
pipeline products and technologies and by
identifying the companies with the most robust
pipeline. - Develop business strategies by
understanding the trends shaping and driving the
global Amyloidosis Therapeutics market. - Drive
revenues by understanding the key trends,
innovative products and technologies, market
segments and companies likely to impact the
global Amyloidosis Therapeutics market in
future. - Formulate effective sales and
marketing strategies by understanding the
competitive landscape and by analyzing the
performance of various competitors. - Identify
emerging players with potentially strong product
portfolios and create effective
counter-strategies to gain a competitive
advantage. - Organize your sales and marketing
efforts by identifying the market categories and
segments that present maximum opportunities for
consolidations, investments and strategic
partnerships. - What the next big thing in the
global Amyloidosis Therapeutics market landscape?
Identify, understand and capitalize. 
4
1.1 List of Tables 51.2 List of Figures 62
Amyloidosis Therapeutics - Introduction 72.1
Overview 72.2 Types of Amyloidosis 72.3
Pathophysiology of Amyloidosis 92.3.1
Pathophysiology of AL Amyloidosis 92.3.2
Pathophysiology of AA Amyloidosis 102.3.3
Pathophysiology of AF Amyloidosis 102.3.4
Pathophysiology of Aß2M Amyloidosis 102.3.5
Pathophysiology of Senile Amyloidosis 102.4
Epidemiology of Amyloidosis 112.4.1 Epidemiology
of AL Amyloidosis 112.4.2 Epidemiology of AA
Amyloidosis 112.4.3 Epidemiology of AF
Amyloidosis 112.4.4 Epidemiology of Aß2M
Amyloidosis 112.4.5 Epidemiology of Senile
Amyloidosis 112.5 Etiology of Amyloidosis 122.6
Risk Factors for Development of Amyloidosis
122.7 Signs and Symptoms of Amyloidosis 122.7.1
Kidney (AL, AA) 122.7.2 Heart (AL, AF, Senile)
122.7.3 Liver (AL, AA, AF) 122.7.4 Skin (AL,
AA) 122.7.5 Gastrointestinal tract (Common in
all Types) 132.7.6 Nervous System (Prominent in
AF) 132.7.7 Endocrine 132.7.8 Joints, Bones,
and Muscles 132.7.9 Respiratory System 132.7.10
Hematopoietic System 132.7.11 Other 132.8
Diagnosis of Amyloidosis 132.8.1 Physical
Examination 142.8.2 Biopsy 142.8.3 Blood Tests
142.8.4 Urine Tests 142.8.5 Imaging Techniques
14c
5
2.9 Treatment and Management Pattern of
Amyloidosis 152.9.1 Treatment of AL Amyloidosis
152.9.2 Treatment of AA Amyloidosis 162.9.3
Treatment of AF Amyloidosis 162.9.4 Treatment of
Aß2M Amyloidosis 162.9.5 Treatment of Senile
Amyloidosis 162.10 Prognosis of Amyloidosis
172.11 GlobalData Pipeline Report Guidance 17 3
Amyloidosis Therapeutics - Market
Characterization 183.1 Amyloidosis Therapeutics
Market Size (2006-2011) - Global 183.2
Amyloidosis Therapeutics Market Forecast
(2011-2019) - Global 193.3 Amyloidosis
Therapeutics Market Size (2006-2011) - The US
203.4 Amyloidosis Therapeutics Market Forecast
(2011-2019) - The US 213.5 Amyloidosis
Therapeutics Market Size (2006-2011) - France
223.6 Amyloidosis Therapeutics Market Forecast
(2011-2019) - France 233.7 Amyloidosis
Therapeutics Market Size (2006-2011) - Germany
243.8 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Germany 253.9 Amyloidosis
Therapeutics Market Size (2006-2011) - Italy
263.10 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Italy 273.11 Amyloidosis
Therapeutics Market Size (2006-2011) - Spain
283.12 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Spain 293.13 Amyloidosis
Therapeutics Market Size (2006-2011) - The UK
303.14 Amyloidosis Therapeutics Market Forecast
(2011-2019) - The UK 313.15 Amyloidosis
Therapeutics Market Size (2006-2011) - Japan
323.16 Amyloidosis Therapeutics Market Forecast
(2011-2019) - Japan 333.17 Drivers and Barriers
for the Amyloidosis Market 343.17.1 Amyloidosis
Therapeutics Market Drivers 343.17.2 Amyloidosis
Therapeutics Market Barriers 343.18 Opportunity
and Unmet Need 35
6
4 Amyloidosis Therapeutics - Competitive
Assessment 374.1 Overview 374.2 Strategic
Competitor Assessment 374.3 Product Profiles for
the Major Off-label Marketed Products in the
Amyloidosis Therapeutics Market 384.3.1
Chemotherapeutic Agents 384.3.2 Steroids
384.3.3 Immunomodulator 394.3.4 New Agent
394.4 Key Takeaway 395 Amyloidosis Therapeutics
- Pipeline Assessment 405.1 Overview 405.2
Strategic Pipeline Assessment 405.3 Amyloidosis
Therapeutics - Pipeline Assessment by Phase of
Development 405.3.1 Amyloidosis Therapeutics -
Recently Approved Drug 405.3.2 Amyloidosis
Therapeutics - Phase III Pipeline 415.3.3
Amyloidosis Therapeutics - Phase II Pipeline
415.3.4 Amyloidosis Therapeutics - Phase I
Pipeline 415.3.5 Amyloidosis Therapeutics -
Pre-clinical Pipeline 415.4 Amyloidosis
Therapeutics - Pipeline by Mechanism of Action
425.5 Technology Trends Analytical Framework
435.6 Recently Approved Drug 445.6.1 Vyndaqel
445.7 Most Promising Drugs Under Clinical
Development 455.7.1 Kiacta 455.8 Key Takeaway
476 Amyloidosis Therapeutics - Clinical Trials
Mapping 486.1 Clinical Trials by Region/Country
(US, EU5 and Japan) 486.2 Clinical Trials by
Phase of Clinical Development 496.3 Clinical
Trials by Trial Status 506.4 Prominent Sponsors
516.5 Brief Profiles of Top Companies
Participating in Therapeutic Clinical Trials 537
Amyloidosis Therapeutics - Strategic Assessment
547.1 Key Events Impacting the Future Market
547.2 Future Market Competition Scenario 558
Amyloidosis Therapeutics - Future Players 56
7
8.1 Introduction 568.2 Company Profiles 578.2.1
Pfizer Inc. 578.2.2 Bellus Health Inc. 599
Amyloidosis Therapeutics - Licensing and
Partnership Deals 6110 Amyloidosis Therapeutics
- Appendix 6210.1 Market Definitions 6210.2
Acronyms 6210.3 Research Methodology 6310.3.1
Coverage 6310.3.2 Secondary Research 6310.3.3
Forecasting 6410.3.4 Primary Research 6610.3.5
Expert Panel Validation 6710.4 Contact Us
6710.5 Disclaimer 6710.6 Bibliography 68 
8
1.1 List of TablesTable 1 Amyloid Fibril
Protein and Precursor 8Table 2 Major Organs
Involved in Most Common Types of Amyloidosis
8Table 3 Amyloidosis Therapeutics Market,
Global, Revenue (bn), 2006-2011 18Table 4
Amyloidosis Therapeutics, Market, Global,
Forecast (bn), 2011-2019 19Table 5 Amyloidosis
Therapeutics Market, The US, Revenue (bn),
2006-2011 20Table 6 Amyloidosis Therapeutics
Market, The US, Forecasts (bn), 2011-2019
21Table 7 Amyloidosis Therapeutics Market,
France, Revenue (m), 2006-2011 22Table 8
Amyloidosis Therapeutics Market, France,
Forecasts (m), 2011-2019 23Table 9 Amyloidosis
Therapeutics Market, Germany, Revenue (m),
2006-2011 24Table 10 Amyloidosis Therapeutics
Market, Germany, Forecasts (m), 2011-2019
25Table 11 Amyloidosis Therapeutics Market,
Italy, Revenue (m), 2006-2011 26Table 12
Amyloidosis Therapeutics Market, Italy, Forecasts
(m), 2011-2019 27Table 13 Amyloidosis
Therapeutics Market, Spain, Revenue (m),
2006-2011 28Table 14 Amyloidosis Therapeutics
Market, Spain, Forecasts (m), 2011-2019 29Table
15 Amyloidosis Therapeutics Market, The UK,
Revenue (m), 2006-2011 30Table 16 Amyloidosis
Therapeutics Market, The UK, Forecasts (m),
2011-2019 31Table 17 Amyloidosis Therapeutics
Market, Japan, Revenue (m), 2006-2011 32Table
18 Amyloidosis Therapeutics Market, Japan,
Forecasts (m), 2011-2019 33Table 19
Amyloidosis Therapeutics - Recently Approved Drug
40Table 20 Amyloidosis Therapeutics - Phase III
and Approved Pipeline, 2011 41Table 21
Amyloidosis Therapeutics - Phase II Pipeline,
2011 41Table 22 Amyloidosis Therapeutics -
Phase I Pipeline, 2011 41Table 23 Amyloidosis
Therapeutics - Pre-clinical Pipeline, 2011
41Table 24 Amyloidosis Therapeutics Market -
Most Promising Drugs Under Clinical Development,
2011 45Table 25 Amyloidosis Therapeutics -
Clinical Trials by Country, 2011 48Table 26
Amyloidosis Therapeutics, Major Markets -
Clinical Trials by Phase, 2011 49Table 27
Amyloidosis Therapeutics, Major Markets, Clinical
Trials by Development Status, 2011 50Table 28
Amyloidosis Therapeutics, Major Markets,
Prominent Sponsors, 2011 52Table 29 Amyloidosis
Therapeutics, Major Markets, Clinical Trials of
Top Companies by Phase, 2011 53Table 30 Pfizer
Inc. - Amyloidosis Pipeline, 2011 59Table 31
Bellus Health - Amyloidosis Pipeline, 2011
59Table 32 Amyloidosis Therapeutics Market -
Future Players 60 
9
1.2 List of FiguresFigure 1 Amyloidosis on
Face 11Figure 2 Amyloidosis Therapeutics
Market, Global, Revenue (bn), 2006-2011
18Figure 3 Amyloidosis Therapeutics Market,
Global, Forecast (bn), 2011-2019 19Figure 4
Amyloidosis Therapeutics Market, The US, Revenue
(bn), 2006-2011 20Figure 5 Amyloidosis
Therapeutics Market, The US, Forecast (bn),
2011-2019 21Figure 6 Amyloidosis Therapeutics
Market, France, Revenue (m), 2006-2011 22Figure
7 Amyloidosis Therapeutics Market, France,
Forecast (m), 2011-2019 23Figure 8 Amyloidosis
Therapeutics Market, Germany, Revenue (m),
2006-2011 24Figure 9 Amyloidosis Therapeutics
Market, Germany, Forecast (m), 2011-2019
25Figure 10 Amyloidosis Therapeutics Market,
Italy, Revenue (m), 2006-2011 26Figure 11
Amyloidosis Therapeutics Market, Italy, Forecast
(m), 2011-2019 27Figure 12 Amyloidosis
Therapeutics Market, Spain, Revenue (m),
2006-2011 28Figure 13 Amyloidosis Therapeutics
Market, Spain, Forecast (m), 2011-2019 29Figure
14 Amyloidosis Therapeutics Market, The UK,
Revenue (m), 2006-2011 30Figure 15 Amyloidosis
Therapeutics Market, The UK, Forecast (m),
2011-2019 31Figure 16 Amyloidosis Therapeutics
Market, Japan, Revenue (m), 2006-2011 32Figure
17 Amyloidosis Therapeutics Market, Japan,
Forecast (m), 2011-2019 33Figure 18
Opportunity and Unmet Need in the Amyloidosis
Therapeutics Market, 2011 35Figure 19 Strategic
Competitor Assessment, 2011 37Figure 20
Amyloidosis Therapeutics Market - Pipeline by
Phase of Development, 2011 40Figure 21
Amyloidosis Therapeutics - Clinical Pipeline by
Mechanism of Action, 2011 42Figure 22
Technology Trends Analytics Framework, 2011
43Figure 23 Technology Trends Analytics
Framework - Description, 2011 44Figure 24
Amyloidosis Therapeutics - Clinical Trials by
Country, 2011 48Figure 25 Amyloidosis
Therapeutics, Major Markets - Clinical Trials by
Phase, 2011 49Figure 26 Amyloidosis
Therapeutics, Major Markets, Clinical Trials by
Development Status, 2011 50Figure 27
Amyloidosis Therapeutics, Major Markets, Overall
Sponsors, 2011 51Figure 28 Amyloidosis
Therapeutics, Major Markets, Prominent Sponsors,
2011 52Figure 29 Amyloidosis Therapeutics,
Major Markets, Clinical Trials of Top Companies
by Phase, 2011 53Figure 30 Amyloidosis
Therapeutics Market, Drivers and Restraints 2011
54Figure 31 Implications for Future Market
Competition in the Amyloidosis Therapeutics
Market, 2011 55Figure 32 Amyloidosis
Therapeutics Market - Pipeline by Company, 2011
56Figure 33 GlobalData Market Forecasting Model
66 Company Mentioned Pfizer Inc.Bellus Health
Inc.
10
Related Reports

• For more information, please visit
• http//www.aarkstore.com/reports/Amyloidosis-Thera
  peutics-Pipeline-Assessment-and-Market-Forecasts-t
  o-2019-198822.html
• Or email us at contact_at_aarkstore.com or call
  919272852585
• More Reports
• http//www.aarkstore.com/publishers/GlobalData-61.
  html
• Bioinformatics Partnering Terms and Agreements
• 2013 Deep Research Report on Global and China
  Human Coagulation Factor ? Industry
• Competing in the European Clinical Chemistry and
  Immunodiagnostic Markets France, Germany, Italy,
  Spain, UK
• Competing in the European Coagulation Testing
  MarketFrance, Germany, Italy, Spain, UK
• Competing in the European Blood Banking
  MarketFrance, Germany, Italy, Spain, UK
• HIV / AIDS Pipeline Review, H1 2013
• Parkinsons Disease Pipeline Review, H1 2013
• Autoimmune Disorders Pipeline Review, H1 2013
• Colon Cancer Pipeline Review, H1 2013
• Metastatic Colorectal Cancer Pipeline Review,
  H1 2013

11
Contact Us Aarkstore EnterpriseTel
912227453309Mobile No08149852585Email
contact_at_aarkstore.comWebsite
http//www.aarkstore.comBlog http//www.emarketr
eports.comhttp//teju-aarkstoreenterprise.blogspo
t.inFollow us on twitter http//twitter.com/aark
storedotcomhttp//in.linkedin.com/in/aarkstoreht
tp//www.facebook.com/aarkstoreenterprise